2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. DGK

DGK

Diacylglycerol kinase;

DGK (Diacylglycerol Kinase) modulates the balance between DAG and phosphatidic acid (PA). DGK phorylates DAG to generate PA. DGK has ten mammalian DGK subtypes (α-κ) with subtype-specific tissue distribution, and they can be classified into 5 types. Among them, DGKα and DGKζ specifically regulate the pool of DAG that is generated as a second messenger after stimulation of the T cell receptor. Whereas, DGKζ is the dominant isoform in T cells. Dysregulation of certain DGK isoforms leads to DAG-activation of PKC, attenuation of insulin signaling, and dysregulation of glucose metabolism. DGK plays a role in many physiological events, including cell proliferation and migration, glucose intake, immunity and neuronal network construction[1][2][3].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-156572
    DGKζ-IN-3
    		Inhibitor
    DGKζ-IN-3 is a DGK-zeta-inhibitor. DGKζ-IN-3 is used in liquid and solid cancer and other diacylglycerol kinase zeta (DGK-ζ) regulation of diseases.
    DGKζ-IN-3
  • HY-156570
    DGKα-IN-3
    		Inhibitor
    DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC50 of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-3
  • HY-160123
    DGKζ-IN-5
    		Inhibitor
    DGKζ-IN-5 is a DGKζ inhibitor (WO2023125681A1; compound A27a).
    DGKζ-IN-5
  • HY-156576
    DGKα-IN-6
    		Inhibitor
    DGKα-IN-6 is a DGKα inhibitor with the IC50 of 1.377 nM, extracted from patent WO2022271650 (compound 143). DGKα-IN-6 has the potential for cancer study.
    DGKα-IN-6
  • HY-171051
    Pasodacigib
    		Inhibitor
    DGKα-IN-9 (example 298) is an inhibitor of DGKα.
    Pasodacigib
  • HY-126599
    Cochlioquinone A
    		Inhibitor
    Cochlioquinone A is a ATP-competive diacylglycerol kinase inhibitor (Ki: 3.1 μM). Cochlioquinone A can be isolated from Drechslera sacchari.
    Cochlioquinone A
  • HY-159649
    BMS-986408
    		Inhibitor
    BMS-986408
  • HY-170426
    DGKζ-IN-9
    		Inhibitor
    DGKζ-IN-9 (compound 73) is a DGKζ inhibitor, with an IC50 ≤200 nM.
    DGKζ-IN-9
  • HY-148174
    JNJ-3790339
    		Inhibitor
    JNJ-3790339, a Ritanserin (HY-10791) analog, is a potent and selective diacylglycerol kinase (DGKα) inhibitor with an IC50 of 9.6 μM. JNJ-3790339 has induction of toxicity in malignant cells, and improves ability to upregulate T cell activation.
    JNJ-3790339
  • HY-156577
    DGKα-IN-7
    		Inhibitor
    DGKα-IN-7 is a DGKα inhibitor with the IC50 of 6.225 nM, extracted from patent WO2022271684 (compound 100). DGKα-IN-7 has the potential for cancer study.
    DGKα-IN-7
  • HY-169317
    DGKζ-IN-6
    		Inhibitor
    DGKζ-IN-6 (compound 40) is an oral active DGKζ inhibitor with the IC50 of 45.5 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases.
    DGKζ-IN-6
  • HY-156573
    DGKα&ζ-IN-1
    		Inhibitor
    DGKα&ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα&ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor.
    DGKα&ζ-IN-1
Cat. No. Product Name / Synonyms Application Reactivity